BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
67.98
-3.41 (-4.78%)
At close: Mar 12, 2026, 4:00 PM EDT
68.00
+0.02 (0.03%)
After-hours: Mar 12, 2026, 4:12 PM EDT
Revenue by Segment
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
|---|
Identifying and Advancing Transformative Medicines to Treat Patients | 502.08M | 221.90M | 9.30M | 77.65M | 69.72M | | | | |
Identifying and Advancing Transformative Medicines to Treat Patients Growth | 126.26% | 2285.27% | -88.02% | 11.38% | 745.14% | | | | |
| 502.08M | 221.90M | 9.30M | 77.65M | 69.72M | | | | |
| 126.26% | 2285.27% | -88.02% | 11.38% | 745.14% | | | | |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
|---|
| 362.50M | 13.31M | 7.90M | - | 69.72M | | | | |
| 2622.66% | 68.57% | - | - | 745.14% | | | | |
Europe, Middle East, and Africa (EMEA) | 127.03M | 132.03M | 55.82K | - | - | | | | |
Europe, Middle East, and Africa (EMEA) Growth | -3.79% | 236439.63% | - | - | - | | | | |
| 12.55M | 76.56M | 1.35M | - | - | | | | |
Asia-Pacific (APAC) Growth | -83.60% | 5575.31% | - | - | - | | | | |
| - | - | - | 76.79M | - | | | | |
| 502.08M | 221.90M | 9.30M | 76.79M | 69.72M | | | | |
| 126.26% | 2285.27% | -87.89% | 10.15% | 745.14% | | | | |
Source: S&P Global Market Intelligence.